Data-driven risk/benefit estimator for multiple sclerosis therapies.

ABSTRACT:

Background

Multiple sclerosis (MS) disease-modifying treatments (DMTs) are tested in patients preselected for favorable risk/benefits ratios but prescribed broadly in clinical practice. We aimed to establish data-driven computations of individualized risk/benefit ratios to optimize MS care.

Methods

We derived determinants of DMTs efficacy on disability progression from re-analysis and integration of 61 randomized, blinded Phase 2b/3 clinical trials that studied 46,611 patients for 91,787 patient-years. From each arm we extracted 80 and computed 30 features to identify and adjust for biases, and to use in multiple regression models. DMTs mortality risks were estimated from age mortality tables modified by published hazard ratios.

Findings

Baseline characteristics of th

SUBMITTER: Bielekova B 

PROVIDER: S-EPMC11451759 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature